Week 3, where are we at?

After the initial amazement and confusion...the shock and awe...arising from the Bomber announcement...wits have been gathered, forces martialled, game plans drawn....says Tim Boreham (Criterion)

Holders in fellow takeover target Cellestis (CST, $3.40) have more to fear. A rebel group opposed to the $3.55-a-share offer claim they account for 34 per cent of the register, and we don't think they're bluffing.

He then advises nervous investors to sell, but he always says that.

More importantly, the Cellestis Research Report is out there for reading, analysis, comment and discussion.. said one commentator

a superb bit of work

thanks to all who did this. i can't imagine the "independent expert" doing anything as comprehensive as this.

As they say in the US, you are most welcome.

Our little group is attracting a bit of attention from foreign markets, (roughly translated)

Qiagen shares added 0.36% on 13.980 euros thus ignoring the Internet blog of the Cellestis Shareholder Action Group (CSAG), according to which have 34.2% of the shareholders of the Australian diagnostics company Cellestis Limited opposed to the aquisition by Qiagen.

Oh really? - now that's what I call drawing a long bow.